AI-backed distant monitoring and digital therapeutics firm Biofourmis added one other $20 million to its Collection D spherical, bringing its elevate to $320 million.
The extension funding comes from Intel Capital, the strategic funding division of chipmaker Intel. The corporate first introduced its Collection D in April, which boosted Biofourmis to unicorn standing with a valuation of $1.3 billion.
Biofourmis additionally introduced it had appointed two new board members: former Tenet Healthcare Chairman and CEO Trevor Fetter and Sachin H. Jain, president and CEO of SCAN Group and SCAN Well being Plan.
“To obtain this extra funding from the enterprise capital arm of a worldwide know-how big throughout an unpredictable time in digital well being funding is additional validation of Biofourmis’ market power and potential and validates that we’re distinguishing ourselves available in the market,” Biofourmis founder and CEO Kuldeep Singh Rajput stated in an announcement. “We’re on a powerful trajectory for continued strategic progress within the coming years by way of prospects, companions and resolution growth.”
Affected person monitoring firm Sibel Well being scored $33 million final week in a Collection B funding spherical led by the Steele Basis for Hope.
The Northwestern College spinout will use the funds to deploy its ANNE One platform for in-home and hospital monitoring. The system, which incorporates two sorts of wearable sensors and an analytics app, acquired FDA 510(okay) clearance final yr.
Sibel stated the Collection B brings its whole elevate to greater than $50 million. The corporate additionally introduced it had appointed Jon Otterstatter, former CEO and cofounder of cardiac monitoring firm Preventice, chairman of the board. Matthew Banet joins the corporate as president from Baxter Worldwide.
“What makes us distinctive as a digital well being firm is that our product is vertically built-in — we consider that every little thing issues, from the adhesive we place on the pores and skin to how the sensor suits on the physique to the ultimate alert a clinician sees for medical decision-making,” Dr. Steve Xu, Sibel CEO and cofounder, stated in an announcement. “We’re proud that our know-how will be probably deployed in each the neonatal intensive care unit and within the house for distant affected person monitoring.”
Atropos Well being, which makes an app that helps physicians entry real-world proof to information affected person care, introduced it had raised $14 million in Collection A funding.
The spherical was led by Breyer Capital with participation from buyers together with Emerson Collective and Boston Millennia Companions. The corporate’s instrument permits suppliers to obtain reviews primarily based on previous affected person encounters that may assist reply scientific questions the place there is not a transparent care path primarily based on established analysis.
Atropos plans to make use of the funds to rent for its industrial crew and develop its oncology product. The startup additionally introduced it had appointed cofounder Brigham Hyde as CEO.
“I’m excited in regards to the huge potential Atropos has to advance how evidence-based medication is practiced throughout the globe,” Hyde stated in an announcement. “I’m honored to get the prospect to guide the enterprise day-to-day and convey customized real-world proof to sufferers and caregivers in all places.”